nach oben

Erschienen in:

01.09.2007 | Original Paper

Expression of Peroxisome Proliferator-Activated Receptor-γ in Colon Cancer: Correlation with Histopathological Parameters, Cell Cycle-Related Molecules, and Patients’ Survival

verfasst von: Stamatios Theocharis, Costas Giaginis, Aikaterini Parasi, Alexandra Margeli, John Kakisis, Emmanuel Agapitos, Gregorios Kouraklis

Erschienen in: Digestive Diseases and Sciences | Ausgabe 9/2007

Einloggen, um Zugang zu erhalten

Abstract

Peroxisome proliferator-activated receptor γ (PPAR-γ), a ligand-activated transcription factor, is a key regulator of adipogenic differentiation and glucose homeostasis. PPAR-γ ligands have recently been demonstrated to affect proliferation and differentiation in cancer cells lines. The aim of the present work was to examine PPAR-γ expression in colon cancer cases. PPAR-γ expression was examined immunohistochemically in 86 colon cancer cases and was correlated with clinicopathological parameters, tumor proliferative capacity, cell cycle-related molecule expression, and patient survival. Positive PPAR-γ immunostaining was prominent in 48 of 86 cases (56%). PPAR-γ positivity was not correlated with Dukes’ stage, histological grade of differentiation, lymph node and liver metastasis, venous invasion, tumor proliferative capacity, or patient survival. A statistically significant correlation was found between PPAR-γ and the expression of cell cycle-related molecules pRb (P < 0.016), cyclin D1 (P <0.009), p16 (P<0.032), and p21 (P<0.033), while a positive trend for cyclin E was also noted (P<0.057). The pattern, intensity, and extent of PPAR-γ expression in positive cases were not correlated with any of the examined variables. Our findings support evidence for participation of this protein in the biological mechanisms underlying carcinogenic evolution in the colon, also suggesting the importance of specific PPAR–γ ligands as cell cycle modulators for a future therapeutic approach in colon cancer.

Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV (1998) Ligand binding and co–activator assembly of the peroxisome proliferators activated receptor–γ. Nature 395:137–143PubMedCrossRef

Willson TM, Brown PJ, Strenbach DD, Henke BR (2000) The PPARs: from orphan receptors to drug discovery. J Med Chem 43:527–550PubMedCrossRef

Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA (1994) Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 135:798–800PubMedCrossRef

Braissant O, Foufelle F, Scotto C, Dauça M, Wahli W (1996) Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, β- and -γ in the adult rat. Endocrinology 137:354–366PubMedCrossRef

Theocharis S, Margeli A, Vielh P, Kouraklis G (2004) Peroxisome proliferator-activated receptor–gamma ligands as cell-cycle modulators. Cancer Treat Rev 30:545–554PubMedCrossRef

Fajas L, Auboeuf D, Raspe E, Shoonjans K, Lefebvre A-M, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J (1997) The organization, promoter analysis and expression of the human PPARγ gene. J Biol Chem 272:18779–18789PubMedCrossRef

Mukherjee R, Jow L, Croston GE, Paterniti JR (1997) Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem 272:8071–8076PubMedCrossRef

Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W (2006) From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 45:120–159PubMedCrossRef

Tolon RM, Castillo AI, Aranda A (1998) Activation of the prolactin protein gene by peroxisome proliferator-activated receptor-alpha appears to be DNA binding-independent. J Biol Chem 273:26652–26661PubMedCrossRef

10.

Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391:79–82PubMedCrossRef

11.

Midgley R, Kerr D (1999) Colorectal cancer. Lancet 353:391–399PubMedCrossRef

12.

Gupta RA, DuBois RN (2002) Controversy: PPAR-γ as a target for treatment of colorectal cancer. Am J Physiol 283:266–269

13.

Bull AW (2003) The role of peroxisome proliferator-activated receptor-gamma in colon cancer and inflammatory bowel disease. Arch Pathol Lab Med 127:1121–1123PubMed

14.

Spiegelman BM (1998) PPARgamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47:507–514PubMedCrossRef

15.

Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C, Spiegelman BM (1998) Differentiation reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4:1946–1952CrossRef

16.

Campbell SE, Stone WL, Whaley SG, Qui M, Krishnan K (2003) Gamma (γ) tocopherol upregulates peroxisome proliferator activated receptor γ expression in SW 480 human colon cancer cell lines. BMC Cancer 3:1–13CrossRef

17.

Kato M, Kusumi T, Tsuchida S, Tanaka M, Sasaki M, Kudo H (2004) Induction of differentiation and peroxisome proliferator-activated receptor γ expression in colon cell lines by troglitazone. J Cancer Res Clin Oncol 130:73–79PubMedCrossRef

18.

Dubois RN, Gupta R, Brockman J, Reddy BS, Krakow SL, Lazar MA (1998) The nuclear eicosanoids receptor, PPARgamma, is aberrantly expressed in colonic cancers. Carcinogenesis 19:49–53PubMedCrossRef

19.

Matthiessen MW, Pedersen G, Albrektsen T, Adamsen S, Fleckner J, Brynskov J (2005) Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas. Scand J Gastoenterol 40:198–205CrossRef

20.

Su GG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flaniqan A, Murthy S, Lazar MA, Wu GD (1999) A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 104:383–389PubMed

21.

Lytle C, Tod TJ, Vo KT, Lee JW, Atkinson RD, Straus DS (2005) The peroxisome proliferator-activated receptor gamma ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency. Inflamm Bowel Dis 11:231–243PubMedCrossRef

22.

Osawa E, Nakajima A, Wada K, Ishimine S, Fujisawa N, Kawamori T, Matsuhashi N, Kadowaki T, Ochiai M, Sekihara H, Nakagama H (2003) Peroxisome proliferator–activated receptor γ ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 124:361–367PubMedCrossRef

23.

Kohno H, Suzuki R, Yasui Y, Hosokawa M, Miyashita K, Tanaka T (2004) Pomegranate seed oil rich in conjugated linolenic acid suppresses chemically induced colon carcinogenesis. Cancer Sci 95:481–486PubMedCrossRef

24.

Jass JR, Atkin WS, Cuzick J, Bussey HJR, Morson BC, Northover JMA, Todd IP (1986) The grading of rectal cancer. Historical perspectives and a multivariate analysis of 446 cases. Histopathology 10:437–459PubMedCrossRef

25.

Theocharis SE, Margeli A, Kanelli H, Spiliopoulou C, Manolis E, Thalhammer T, Koutselinis A (1986) Peroxisome proliferator activated receptor γ expression in two animal models of chemically induced liver injury and regeneration. Hepatology 20:A332

26.

He T-C, Chan TA, Vogelstein B, Kinzler KW (1999) PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99:335–345PubMedCrossRef

27.

Fajas L, Debril MB, Auwerx J (2001) Peroxisome proliferator-activated receptor-γ: from adipogenesis to carcinogenesis. J Mol Endocrinol 27:1–9PubMedCrossRef

28.

Jalving M, Koornstra JJ, De Jong S, De Vries EG, Kleibeuker JH (2005) Review article: The potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer. Aliment Pharmacol Ther 21:321–339PubMedCrossRef

29.

Han SW, Greene ME, Pitts J, Wada RK, Sidell N (2001) Novel expression and function of peroxisome proliferator-activated receptor gamma (PPARgamma) in human neuroblastoma. Clin Cancer Res 7:98–104PubMed

30.

Zhang GY, Ahmed N, Riley C, Oliva K, Barker G, Quinn MA, Rice GE (2005) Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma. Br J Cancer 92:113–119PubMedCrossRef

31.

Theocharis S, Kanelli H, Politi E, Margeli A, Karkandaris C, Philippides T, Koutselinis A (2002) Expression of peroxisome proliferator-activated receptor-gamma in non-small cell lung carcinoma: correlation with histological type and grade. Lung Cancer 36:249–255PubMedCrossRef

32.

Jiang WG, Redfern A, Bryce RP, Mansel RE (2000) Peroxisome proliferator activated receptor-gamma (PPAR-gamma) mediates the action of gamma linolenic acid in breast cancer cells. Prostaglandins Leukot Essent Fatty Acids 62:119–127PubMedCrossRef

33.

Katagiri Y, Takeda K, Yu ZX, Ferrans VJ, Ozato K, Guroff G (2000) Modulation of retinoid signaling through NGF-induced nuclear export of NGFI-B. Nat Cell Biol 2:435–440PubMedCrossRef

34.

Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA, de la Chapelle A, Spiegelman BM, Eng C (1999) Loss-of-function mutations in PPARγ associated with human colon cancer. Molecular Cell 3:799–804PubMedCrossRef

35.

Wakino S, Kintscher U, Kim S, Yin F, Hsueh WA, Law RE (2000) Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1→S transition in vascular smooth muscle cells. J Biol Chem 275:22435–22441PubMedCrossRef

36.

Morrison RF, Farmer SR (1999) Role of PPARgamma in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18 (INK4c) and p21 (Waf1/Cip1), during adipogenesis. J Biol Chem 274:17088–17097PubMedCrossRef

37.

Yoshizumi T, Ohta T, Ninomiya I, Terada I, Fushida S, Fujimura T, Nishimura G, Shimizu K, Yi S, Miwa K (2004) Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. Int J Oncol 25:631–639PubMed

38.

Kim E, Chen F, Wang CC, Harrison LE (2006) CDK5 is a novel regulatory protein in PPARgamma ligand antiproliferation. Int J Oncol 28:191–194PubMed

39.

Chen F, Harrison LE (2005) Ciglitazone-induced cellular anti-proliferation p27kip1 protein levels through both increased transcriptional activity and inhibition of proteasome degradation. Cell Signal 17:809–816PubMedCrossRef

40.

Yin F, Wakino S, Liu Z, Kim S, Hsueh WA, Collins AR, Van Herle AJ, Law RE (2001) Troglitazone inhibits growth of MCF-7 breast carcinoma by targeting G1 cell cycle regulators. Biochem Biophys Res Commun 286:916–922PubMedCrossRef

41.

Guan YF, Zhan YH, Breyer RM, Davis L, Breyer MD (1999) Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia 1:330–339PubMedCrossRef

42.

Hupfeld CJ, Weiss RH (2001) TZDs inhibit vascular smooth muscle cell growth independently of the cyclin kinase inhibitors p21 and p27. Am J Physiol Endocrinol Metab 281:E207–E216PubMed

43.

Lefebvre AM, Chen I, Desreumaux P, Najib J, Fruchart JC, Geboes K, Briggs M, Heyman R, Auwerx J (1998) Activation of peroxisome proliferator–activated receptor gamma promotes the development of colon tumors in C57BL/6J–APCMin/+mice. Nat Med 4:1053–1057PubMedCrossRef

44.

Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, Thomazy VA, Evans RM (1998) Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med 4:1058–1061PubMedCrossRef

45.

Seed B (1998) PPAR gamma and colorectal carcinoma: conflicts in a nuclear family. Nat Med 4:1004–1005PubMedCrossRef

46.

Smalley WE, Dubois RN (1997) Colorectal cancer and non steroidal antiinflammatory drugs. Adv Pharmacol 39:1–20PubMedCrossRef

47.

Prescott SM, White RL (1996) Self-promotion? Intimate connections between APC and prostaglandin H synthetase-2. Cell 87:783–786PubMedCrossRef

48.

Shiff SJ, Qiao L, Tsai LL, Rigas B (1995) Sulindac sulfide, an aspirin-like compound, inhbits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 96:491–503PubMed

49.

Lim H, Gupta RA, Ma WG, Paria BC, Moller DE, Morrow JD, DuBois RN, Trzaskos JM, Dey SK (1999) Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes Dev 13:1561–1574PubMed

50.

Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesia JP, Marco CC, McKee LJ, Bauer TL, Caro JF (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334:292–295PubMedCrossRef

51.

Kinzler KW, Vogelstein B (1996) Lessons from hereditary colorectal cancer. Cell 87:159–170PubMedCrossRef

52.

Giovanucci E, Willet WC (1994) Dietary factors and risk of colon cancer. Ann Med 26:443–452

53.

Wasan HS, Novelli M, Bee J, Bodmer WF (1997) Dietary fat influences on polyp phenotype in multiple intestinal neoplasia mice. Proc Natl Acad Sci USA 94:3308–3313PubMedCrossRef

54.

Wu GD (2000) A nuclear receptor to prevent colon cancer. N Engl J Med 342:651–653PubMedCrossRef

55.

Jansson EA, Are A, Greicius G, Kuo IC, Kelly D, Arulampalam V, Pettersson S (2005) The Wnt/beta-catenin signaling pathway targets PPARgamma activity in colon cancer cells. Proc Natl Acad Sci USA 102:1460–1465PubMedCrossRef

56.

Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM (1995) A prostaglandin J2 metabolite binds peroxisome proliferator–activated receptor gamma and promotes adipocyte differentiation. Cell 83:813–819PubMedCrossRef

57.

Marin HE, Peraza MA, Billin AN, Willson TM, Ward JM, Kennett MJ, Gonzalez FJ, Peters JM (2006) Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis. Cancer Res 66:4394–4401PubMedCrossRef

58.

Zuo X, Wu Y, Morris JS, Stimmel JB, Leesnitzer LM, Fischer SM, Lippman SM, Shureiqi I (2006) Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity. Oncogene 25:1225–1241PubMedCrossRef

Titel: Expression of Peroxisome Proliferator-Activated Receptor-γ in Colon Cancer: Correlation with Histopathological Parameters, Cell Cycle-Related Molecules, and Patients’ Survival
verfasst von: Stamatios Theocharis
Costas Giaginis
Aikaterini Parasi
Alexandra Margeli
John Kakisis
Emmanuel Agapitos
Gregorios Kouraklis
Publikationsdatum: 01.09.2007
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 9/2007
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-007-9794-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2007

Association Among C-Reactive Protein, Fatty Liver Disease, and Cardiovascular Risk

Oxidative Stress and Pathogenesis of Inflammatory Bowel Disease: An Epiphenomenon or the Cause?

Peptic Ulcer in Gastric Heterotopia of the Gallbladder Without Evidence of Helicobacter pylori Infection

The Role of Zinc and Metallothionein in the Dextran Sulfate Sodium-Induced Colitis Mouse Model

Comparison of Clinical Features and Patient Background in Functional Dyspepsia and Peptic Ulcer

Serum Mannan-Binding Lectin Levels in Patients with Celiac Disease: An Analysis of Clinical and Autoimmune Features